EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.

EPR (electron paramagnetic resonance) has been used to study interactions of the Ru(III) anticancer compounds imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and indazolium [trans-RuCl4(1H-indazole)2] (KP1019) with isolated subcellular components and whole cells of the yeast Saccharomyces cerevisiae. These studies are the first to probe the intracellular speciation of ruthenium using the EPR technique. Initially, NAMI-A and KP1019 were incubated at 30 °C, for time periods up to 24 hours with isolated cell wall, mitochondrial, cytoplasmic, and nuclear fractions of S. cerevisiae. EPR measurements demonstrate that NAMI-A initially forms non-coordinate interactions with each cell component. After longer incubation times these are replaced by coordinated species, particularly with cytoplasmic proteins. KP1019 shows a greater tendency to coordinate directly with cell components, demonstrating significant interactions with mitochondria and cytoplasmic proteins. Subsequently, each complex was incubated with whole cells of S. cerevisiae at 30 °C and whole-cell EPR measurements detected Ru(III) species in measurable concentrations even after 24 hours of incubation. Analysis of the resulting EPR spectra suggests NAMI-A interacts predominantly with cell walls, while KP1019 was found to be coordinating with both the mitochondrial and cytoplasmic protein fractions. Comparison of the signal intensity of these data with those from incubation with whole cells at 4 °C indicates different modes of transmembrane transport for each complex. These studies demonstrate that EPR can provide valuable insight into the oxidation state and speciation of ruthenium compounds in cellular environments.

[1]  M. H. Torre Metal Ions in Biology and Medicine , 2013 .

[2]  P. A. Lay,et al.  Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study. , 2013, Chemistry.

[3]  Gabriel E Büchel,et al.  X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) , 2013, Journal of Medicinal Chemistry.

[4]  Z. Salvadó,et al.  Effect of low temperature upon vitality of Saccharomyces cerevisiae phospholipid mutants , 2012, Yeast.

[5]  B. Lai,et al.  Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells. , 2012, Metallomics : integrated biometal science.

[6]  Michael I Webb,et al.  Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin. , 2012, Inorganic chemistry.

[7]  B. Keppler,et al.  Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies , 2012, JBIC Journal of Biological Inorganic Chemistry.

[8]  A. Bergamo,et al.  Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. , 2011, Dalton transactions.

[9]  V. DeRose,et al.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro , 2011, JBIC Journal of Biological Inorganic Chemistry.

[10]  W. Berger,et al.  Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019 , 2011, JBIC Journal of Biological Inorganic Chemistry.

[11]  P. Dyson,et al.  Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. , 2011, Metallomics : integrated biometal science.

[12]  Michael I Webb,et al.  Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin. , 2011, Dalton transactions.

[13]  W. Berger,et al.  Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 , 2010, JBIC Journal of Biological Inorganic Chemistry.

[14]  Michael I Webb,et al.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR , 2010, JBIC Journal of Biological Inorganic Chemistry.

[15]  P. A. Lay,et al.  Recent developments in ruthenium anticancer drugs. , 2009, Metallomics : integrated biometal science.

[16]  Sophie Laurent,et al.  How to quantify iron in an aqueous or biological matrix: a technical note. , 2009, Contrast media & molecular imaging.

[17]  W. Hagen Metallomic EPR spectroscopy. , 2009, Metallomics : integrated biometal science.

[18]  R. Hilger,et al.  Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study , 2009, Anti-cancer drugs.

[19]  M. Brustolon,et al.  Electron paramagnetic resonance : a practitioner's toolkit , 2009 .

[20]  M. Jakupec,et al.  Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. , 2009, Journal of analytical atomic spectrometry.

[21]  R. Hilger,et al.  Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors. , 2009, International journal of clinical pharmacology and therapeutics.

[22]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[23]  B. Keppler,et al.  Electron-transfer activated metal-based anticancer drugs , 2008 .

[24]  R. Eldik,et al.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin , 2008, JBIC Journal of Biological Inorganic Chemistry.

[25]  M. Jakupec,et al.  Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.

[26]  A. Timerbaev,et al.  Probing the stability of serum protein–ruthenium(III) drug adducts in the presence of extracellular reductants using CE , 2007, Electrophoresis.

[27]  R. Eldik,et al.  Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution , 2007, JBIC Journal of Biological Inorganic Chemistry.

[28]  W. Hagen EPR spectroscopy as a probe of metal centres in biological systems. , 2006, Dalton transactions.

[29]  P. Dyson,et al.  The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. , 2006, International journal of oncology.

[30]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[31]  Christian G Hartinger,et al.  Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. , 2006, Chemical reviews.

[32]  G. Sava,et al.  Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion , 2006, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Timerbaev,et al.  Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient. , 2005, International journal of clinical pharmacology and therapeutics.

[34]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[35]  G. Sava,et al.  Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[36]  S. Andrews,et al.  Mössbauer spectroscopy and electron paramagnetic resonance studies of iron metabolites inPseudomonas aeruginosa: Fe2+ and Fe3+ ferritin in57ferripyoverdine incubated cells and57ferric citrate fed cells , 1992, Biometals.

[37]  B. Keppler,et al.  A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. , 2004, Journal of inorganic biochemistry.

[38]  G. Sava,et al.  Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. , 2004, European journal of cancer.

[39]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[40]  J. G. Haasnoot,et al.  The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. , 2004, Journal of inorganic biochemistry.

[41]  G. Allmaier,et al.  Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy , 2004 .

[42]  A. Bergamo,et al.  Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin , 2003, Investigational New Drugs.

[43]  M. Zoroddu,et al.  Electron paramagnetic resonance studies and effects of vanadium in Saccharomyces cerevisiae , 2004, Biometals.

[44]  Gonzalo Colmenarejo,et al.  In silico prediction of drug‐binding strengths to human serum albumin , 2003, Medicinal research reviews.

[45]  G. Pezzoni,et al.  Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  J. Beijnen,et al.  A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. , 2002, International journal of pharmaceutics.

[47]  A. Bergamo,et al.  Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells , 2002, Cancer Chemotherapy and Pharmacology.

[48]  B. Keppler,et al.  Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS , 2001, JBIC Journal of Biological Inorganic Chemistry.

[49]  T. I. Vakul’skaya,et al.  Electron Paramagnetic Resonance in Biochemistry and Medicine , 2001 .

[50]  B. Keppler,et al.  Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III). , 2000, Journal of inorganic biochemistry.

[51]  W. Peti,et al.  Solvolysis of the Tumor-Inhibiting Ru(III)-Complex trans-Tetrachlorobis(Indazole)Ruthenate(III) , 2000, Metal-based drugs.

[52]  B. Keppler,et al.  Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) an , 1996, Metal-based drugs.

[53]  M. Breitenbach,et al.  Sites of copper binding in Streptomyces pilosus , 1995 .

[54]  John A. Weil,et al.  Electron paramagnetic resonance : elementary theory and practical applications , 1995 .

[55]  B. Keppler,et al.  The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. , 1994, Journal of Biological Chemistry.

[56]  S. Nair,et al.  Cellular distribution of hexa and trivalent chromium in Pseudomonas aeruginosa. , 1993, Indian journal of experimental biology.

[57]  E. Zinser,et al.  Sterol composition of yeast organelle membranes and subcellular distribution of enzymes involved in sterol metabolism , 1993, Journal of bacteriology.

[58]  E. Alessio,et al.  Synthesis and characterization of two new classes of ruthenium(III)-sulfoxide complexes with nitrogen donor ligands (L): Na[trans-RuCl4(R2SO)(L)] and mer, cis-RuCl3(R2SO)(R2SO)(L). The crystal structure of Na[trans-RuCl4(DMSO)(NH3)] · 2DMSO, Na[trans-RuCl4(DMSO)(Im)] · H2O, Me2CO (Im = imidazole) an , 1993 .

[59]  D. Petering,et al.  Interactions of 1,10-phenanthroline and its copper complex with Ehrlich cells. , 1992, Free radical biology & medicine.

[60]  R. Busse,et al.  On-line detection of nitric oxide formation in liquid aqueous phase by electron paramagnetic resonance spectroscopy. , 1991, Analytical biochemistry.

[61]  E. Alessio,et al.  Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexes , 1991 .

[62]  D. Burns,et al.  Application of quantitative EPR , 1990, Philosophical Transactions of the Royal Society of London. Series A: Physical and Engineering Sciences.

[63]  D. Kosman,et al.  Intracellular Mn (II)-associated superoxide scavenging activity protects Cu,Zn superoxide dismutase-deficient Saccharomyces cerevisiae against dioxygen stress. , 1989, The Journal of biological chemistry.

[64]  D. Petering,et al.  ESR studies of the interaction of copper(II)GHK, histidine, and Ehrlich cells. , 1989, Journal of inorganic biochemistry.

[65]  M. Mestdagh,et al.  Preliminary ESR study of Mn(II) retention by the yeast Saccharomyces. , 1988, Canadian journal of microbiology.

[66]  J. Duffus,et al.  Yeast : a practical approach , 1988 .

[67]  D. Petering,et al.  ESR studies of molecular interactions of copper(II) nirvanol and copper(II) diisopropylsalicylate with Ehrlich ascites tumor cells. , 1987, Journal of inorganic biochemistry.

[68]  P. Rouxhet,et al.  ESR study of copper(II) retention by entire cell, cells walls, and protoplasts of Saccharomyces cerevisiae. , 1987, Canadian journal of microbiology.

[69]  G. Sudlow,et al.  Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.

[70]  G. Sudlow,et al.  The characterization of two specific drug binding sites on human serum albumin. , 1975, Molecular pharmacology.